tetano
Editor, Senior Moderator
Inflammopharmacology. 2019 Aug 24. doi: 10.1007/s10787-019-00633-1. [Epub ahead of print]
[h=1]Polygalasaponin F treats mice with pneumonia induced by influenza virus.[/h] Ye Y[SUP]1[/SUP], Wang H[SUP]1[/SUP], Liu J[SUP]2[/SUP], Zhao F[SUP]1[/SUP], Xu P[SUP]3[/SUP].
[h=3]Author information[/h] 1 Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist., Guangzhou, 510405, Guangdong, People's Republic of China. 2 Basic Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. 3 Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist., Guangzhou, 510405, Guangdong, People's Republic of China. xupeiping@gzucm.edu.cn.
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza is an acute viral respiratory illness that causes high morbidity and mortality globally. Therapeutic actions are limited to vaccines and a few anti-viral drugs. Polygala (P.) japonica herba is rich in Polygalasaponin F (PSF, C[SUB]53[/SUB]H[SUB]86[/SUB]O[SUB]23[/SUB]), used for acute bronchitis, pharyngitis, pneumonia, amygdalitis, and respiratory tract infections treatment in China. Hypercytokinemia is often correlated with severe pneumonia caused by several influenza viruses. PSF was reported to have anti-inflammatory effects and its mechanism is associated with the nuclear factor (NF)-κB signaling pathway. The action of PSF to alleviate pulmonary inflammation caused by influenza A virus (IAV) infection requires careful assessment. In the present study, we evaluated the effect and mechanism of PSF on mice with pneumonia caused by influenza H1N1 (A/FM/1/47).
[h=4]METHODS:[/h] Mice were infected intranasally with fifteen 50% mouse lethal challenge doses (MLD[SUB]50[/SUB]) of influenza virus. BALB/c mice were treated with PSF or oseltamivir (oral administration) for 2 h post-infection and received concomitant treatment for 5 days after infection. On day 6 post-infection, 10 mice per group were killed to collect related samples, measure body weight and lung wet weight, and detect the viral load, cytokine, prostaglandins, pathological changes, and cell pathway protein expression in the lungs. In addition, the survival experiments were carried out to investigate the survival of mice. The expression profile of cell pathway proteins was detected and analyzed using a broad pathway antibody array and confirmed the findings from the array by western blotting.
[h=4]RESULTS:[/h] Polygalasaponin F and oseltamivir can protect against influenza viral infection in mice. PSF and oseltamivir significantly relieved the signs and symptoms, reduced body weight loss, and improved the survival rate of H1N1-infected mice. Moreover, PSF efficiently decreased the level of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-4, interferon (IFN)-γ, thromboxane A[SUB]2[/SUB] (TXA[SUB]2[/SUB]), and prostaglandin E[SUB]2[/SUB] (PGE[SUB]2[/SUB]) in lung tissues of mice infected with influenza virus (p < 0.05-0.01). Oseltamivir had a similar effect to lung cytokine of PSF, but did not decrease the levels of TXA[SUB]2[/SUB] and PGE[SUB]2[/SUB]. There was a twofold or greater increase in four cell pathway protein, namely NF-κB p65 (2.68-fold), I-kappa-B-alpha (IκBα) (2.56-fold), and MAPK/ERK kinase 1 (MEK1) (7.15-fold) assessed in the array induced by influenza virus. Western blotting showed that the expression of these proteins was significantly decreased in lung after influenza virus challenge in PSF and oseltamivir-treated mice (p < 0.05-0.01).
[h=4]CONCLUSION:[/h] Polygalasaponin F appears to be able to augment protection against IAV infection in mice via attenuation of pulmonary inflammatory responses. Its effect on IAV-induced pulmonary inflammation was associated with suppression of Raf/MEK/ERK and NF-κB expressions.
[h=4]KEYWORDS:[/h] Influenza virus; Pneumonia; Polygalasaponin F; Signaling pathway
PMID: 31446589 DOI: 10.1007/s10787-019-00633-1
[h=1]Polygalasaponin F treats mice with pneumonia induced by influenza virus.[/h] Ye Y[SUP]1[/SUP], Wang H[SUP]1[/SUP], Liu J[SUP]2[/SUP], Zhao F[SUP]1[/SUP], Xu P[SUP]3[/SUP].
[h=3]Author information[/h] 1 Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist., Guangzhou, 510405, Guangdong, People's Republic of China. 2 Basic Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. 3 Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist., Guangzhou, 510405, Guangdong, People's Republic of China. xupeiping@gzucm.edu.cn.
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza is an acute viral respiratory illness that causes high morbidity and mortality globally. Therapeutic actions are limited to vaccines and a few anti-viral drugs. Polygala (P.) japonica herba is rich in Polygalasaponin F (PSF, C[SUB]53[/SUB]H[SUB]86[/SUB]O[SUB]23[/SUB]), used for acute bronchitis, pharyngitis, pneumonia, amygdalitis, and respiratory tract infections treatment in China. Hypercytokinemia is often correlated with severe pneumonia caused by several influenza viruses. PSF was reported to have anti-inflammatory effects and its mechanism is associated with the nuclear factor (NF)-κB signaling pathway. The action of PSF to alleviate pulmonary inflammation caused by influenza A virus (IAV) infection requires careful assessment. In the present study, we evaluated the effect and mechanism of PSF on mice with pneumonia caused by influenza H1N1 (A/FM/1/47).
[h=4]METHODS:[/h] Mice were infected intranasally with fifteen 50% mouse lethal challenge doses (MLD[SUB]50[/SUB]) of influenza virus. BALB/c mice were treated with PSF or oseltamivir (oral administration) for 2 h post-infection and received concomitant treatment for 5 days after infection. On day 6 post-infection, 10 mice per group were killed to collect related samples, measure body weight and lung wet weight, and detect the viral load, cytokine, prostaglandins, pathological changes, and cell pathway protein expression in the lungs. In addition, the survival experiments were carried out to investigate the survival of mice. The expression profile of cell pathway proteins was detected and analyzed using a broad pathway antibody array and confirmed the findings from the array by western blotting.
[h=4]RESULTS:[/h] Polygalasaponin F and oseltamivir can protect against influenza viral infection in mice. PSF and oseltamivir significantly relieved the signs and symptoms, reduced body weight loss, and improved the survival rate of H1N1-infected mice. Moreover, PSF efficiently decreased the level of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-4, interferon (IFN)-γ, thromboxane A[SUB]2[/SUB] (TXA[SUB]2[/SUB]), and prostaglandin E[SUB]2[/SUB] (PGE[SUB]2[/SUB]) in lung tissues of mice infected with influenza virus (p < 0.05-0.01). Oseltamivir had a similar effect to lung cytokine of PSF, but did not decrease the levels of TXA[SUB]2[/SUB] and PGE[SUB]2[/SUB]. There was a twofold or greater increase in four cell pathway protein, namely NF-κB p65 (2.68-fold), I-kappa-B-alpha (IκBα) (2.56-fold), and MAPK/ERK kinase 1 (MEK1) (7.15-fold) assessed in the array induced by influenza virus. Western blotting showed that the expression of these proteins was significantly decreased in lung after influenza virus challenge in PSF and oseltamivir-treated mice (p < 0.05-0.01).
[h=4]CONCLUSION:[/h] Polygalasaponin F appears to be able to augment protection against IAV infection in mice via attenuation of pulmonary inflammatory responses. Its effect on IAV-induced pulmonary inflammation was associated with suppression of Raf/MEK/ERK and NF-κB expressions.
[h=4]KEYWORDS:[/h] Influenza virus; Pneumonia; Polygalasaponin F; Signaling pathway
PMID: 31446589 DOI: 10.1007/s10787-019-00633-1